Format

Send to

Choose Destination
Pharm Res. 2015 Nov;32(11):3470-9. doi: 10.1007/s11095-014-1584-z. Epub 2014 Dec 2.

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.

Author information

1
Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech, Inc, 1 DNA Way (Mailstop 463A), South San Francisco, CA, 94080, USA. kamath.amrita@gene.com.
2
Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech, Inc, 1 DNA Way (Mailstop 463A), South San Francisco, CA, 94080, USA.

Abstract

Antibody drug conjugates (ADCs) are an emerging new class of targeted therapeutics for cancer that use antibodies to deliver cytotoxic drugs to cancer cells. There are two FDA approved ADCs on the market and over 30 ADCs in the clinical pipeline against a number of different cancer types. The structure of an ADC is very complex with multiple components and considerable efforts are ongoing to determine the attributes necessary for clinical success. Understanding the pharmacokinetics of an ADC and how it impacts efficacy and toxicity is a critical part of optimizing ADC design and delivery i.e., dose and schedule. This review discusses the pharmacokinetic considerations for an ADC and tools and strategies that can be used to evaluate molecules at the preclinical stage.

KEYWORDS:

antibody drug conjugate; biotherapeutics; cancer; pharmacokinetics; preclinical

PMID:
25446773
PMCID:
PMC4596897
DOI:
10.1007/s11095-014-1584-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center